Paratek Pharmaceuticals

[Available On-Demand]
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The company’s lead FDA approved commercial product, NUZYRA® (omadacycline) is a once-daily intravenous and oral antibiotic for the treatment of adult patients with CABP and ABSSSI caused by susceptible pathogens.
Ticker:
PRTK
Exchange:
NYSE
Company Type:
Company Website:
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
NUZYRA (omadacycline)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
President & Chief Commercial Officer
Paratek Pharmaceuticals, Inc